FDA Panel Rejects Merck’s Gefapixant For Chronic Cough, Calls For Better Endpoints

 
• By Brenda Sandburg
  
Coughing woman
Evidence does not support use of Merck's gefapixant for treatment of chronic cough, FDA advisory committee concludes • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers